Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

169 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exploiting a proprietary tech platform to develop biomolecular tools for therapeutic & synthetic biology applications PartitionBioTM Exploiting a novel proprietary technology platform to develop biomolecular tools for the use in therapeutic and synthetic biology applications.

132 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing a new generation of vaccines and immunotherapeutic drugs Virometix is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases

150 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Vaccines for the future Sur la base d'une technologie innovante, brevetée, AIOVA a pour ambition de développer et commercialiser des vaccins innovants, à forte valeur ajoutée, à ses clients industriels pharmaceutiques. AIOVA se positionne dans la lutte contre les pandémies émergentes ou ré-émergentes et mortelles de l’homme et l’animal, dans une approche OneHealth, et notamment les grippes (grippes humaines et aviaires), les maladies type SIDA, et, très récemment, les maladies dues aux coronavirus tel le SARS-CoV-2, responsable de la pandémie actuelle de COVID-19. Les vaccins sont conçus à partir d’une plateforme ADN, brevetée, et ont pour propriétés d’activer, chez l’hôte …

60 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

165 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Development of CAR-T cell based cancer therapies T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories. T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

less complexity. more biology. At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

931 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Valora Therapeutics is a privately held biotech, co-founded with Carolyn Bertozzi, developing multispecific antibodies and T cell engagers that break the glyco-immune checkpoint. Our proprietary AbLecTM and T-LecTM platforms combine precise tumor targeting with localized glyco-immune checkpoint disruption to generate therapeutics with superior anticancer activity without the requirement for delivering toxic payloads. Valora's discovery engine was built on a $30M Seed Round led by Avalon BioVentures.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

125 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We fight for human health - we are the RNA people CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics …

67 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advanced Biomaterials for Regenerative Medicine Tensive is a biomedical company developing advanced biomaterials for regenerative medicine applications, with a current focus on reconstructive surgery after breast cancer.

77 similar entities Type: Startup Activities: deeptech healthtech Technologies: New Materials Synthetic Biology

Health Research & Development Center BIONOVEO offers project leaders, whether they are industrial or academic, the skills and biological, technical and methodological resources necessary for the development of new therapeutic and diagnostic strategies, as well as their production processes.

169 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Rwanda FDA's mission is to regulate medical products, processed foods, household products, and tobacco and tobacco products to ensure their quality and safety so as to protect the population of Rwanda from defective, falsified and substandard products.

59 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Inscripta merged with Manus in April 2025 to establish a unique end-to-end platform for scalable development, biomanufacturing, and commercialization of bioalternative products. By combining Inscripta’s advanced whole-genome engineering technologies with Manus’ proven cell factory engineering platform, biomanufacturing expertise, and commercialization capabilities, the merged company – Manus – is uniquely positioned to deliver commercial momentum and scaled profitability in next-generation industrial biotechnology.

61 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Democratising synthetic DNA to enhance daily life around the world. Our mission is to democratise the power of DNA, enhancing daily life around the world. In pursuit of this goal, we make products that harness the remarkable capabilities of DNA. DNA Data Storage and DNA Sequencing

Type: Startup Activities: biotech deeptech Technologies: Data Analytics

Improving health and life for people living with diabetes, obesity and other cardiometabolic diseases Arecor is a clinical-stage biotech company, developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Superior Products for Diabetes Treatment, Liquid Products with Superior Stability, Lyo-to-liquid switch, IV to SC switch, High Concentration mAbs, Ready-to-Use (RTU) Formats, Differentiated Biosimilars, Vaccine Stability, and Oral Delivery of Peptides

206 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Changing the way we see the gut Motilent is a technology SME focused on delivering innovative services for the quantitative investigation of the gut. Motilent champions the use of novel MRI post-processing software as a cheaper and safer biomarker for Gastrointestinal and Bowel Disorders, providing quantitative end points for research, drug development and clinical decision-making.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing Breakthrough Cancer Immunotherapies Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. Cancer Immunotherapies, Phosphatases, Immuno-Oncology, Checkpoint inhibitors, CAR-T, and Solid tumours and Lymphomas

344 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeted treatment of serious infections mycoBiologics is a University of Aberdeen biotech spinout company which is dedicated to developing new antibody therapies to improve the survival of patients suffering from life-threatening, drug-resistant infections. Antibody therapy, Anti-infectives, Antifungal, Antibacterial, and Drug discovery

298 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Memo Therapeutics AG, an Ipsen company, is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections.

215 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

512 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

359 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Nevezyne develops its own protein expression systems and offers its expertise in the expression of recombinant proteins, for research programs, for diagnosis in animal and human health Protein Expression, Baculovirus System, Protein Purification, and Bacterial System

219 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Shielding life from Radiation CellTereo offers patented cryopreservation technology that shields biological samples from harmful radiation during long-term storage. This includes specialized radiation shielding in cryostats and radiation detection services to maintain the integrity and viability of preserved materials. Supported by: SATT Linksium Grenoble Alpes & Station F, Paris.

69 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology New Materials

Vetbiolix develops innovative products for the treatment and prevention of chronic diseases affecting the chi Vetbiolix develops innovative products for the treatment and prevention of chronic diseases affecting dogs and cats.

110 similar entities Type: Startup Activities: pettech deeptech biotech healthtech Technologies: Synthetic Biology

Built around safe-by-design concept, Adjuvatis is committed for innovative formulations to improve pharmaceuticals Adjuvatis, a French startup in biotechnology, develops innovative safe-by-design delivery systems to help laboratories and pharmaceutical companies in vaccine formulation as adjuvants and in drug delivery as vectors for oncology, dermatology, infections, etc. Our first technology, called i-Particles®, is based on 200 nm-diameter particles composed of poly-lactic acid only (any surfactant and solvents) for formulation of hydrophobic molecules in the particle core and surface functionalization of peptides. Our second technology, i-LipoP®, consists in i-Particles® covered by lipidic bilayers at their surface for vectorization of nucleic acids and …

100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

227 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Subsidiary of BioNTech SE, now trading as BioNTech R&D (Austria). Developing novel anti-bacterials. BioNTech R&D Austria GmbH (formerly: PhagoMed Biopharma GmbH) is a fully owned subsidiary of BioNTech. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial infections. Biotech

61 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Pioneering therapies for oncogene-driven cancers Haptena is a biotech company founded in 2025 by Professors Chiara Ambrogio and Roberto Chiarle, with the goal of advancing next-generation immunotherapies for genetically defined cancers. Our mission is to bridge the precision of targeted therapies and the transformative potential of immune-based treatments to deliver more durable options for patients with some of the most challenging tumors.

241 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

137 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Scalable Bioreactor Solutions for Sensitive Cell Culture – From Research to Industrial Production our disruptive bioreactors will allow you to cultivate the most demanding cells (induced pluripotent stem cells, stem cells, lymphocytes, etc.) from small (L) to large scale (m3). The patented principle allows the cultivation of cells in 3D without using any suspension tool (propellers, blades, turbine, etc.). In brief, with our bioreactors, you have access to an easy bioproduction process at high yield of production, scalable up to industrial scale without changing anything in the process ...

77 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Saving lives through affordable and efficient bacterial vaccines Gefjon Pharma has developed a groundbreaking platform technology based on our unique hyper vesiculating outer membrane vesicle (OMV) technology. This combined with our unique extraction method enable high-yield cost-effective production of bio-industrials and therapeutics. Our first product is a revolutionary broad-protective bacterial E. coli vaccine targeting poultry production. We have PoC for both the vaccine and an aerosol application method. With E. coli being the single most important cause of mortality and infections in poultry, we will significantly reduce global consumption of antimicrobials, thereby minimizing the development of antimicrobial resistance (AMR), improve …

89 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Gone are the days of frozen logistics; welcome to the new era of shelf-stable science with Atelerix. Crafting shelf-stable science inspired by hedgehogs, Atelerix is the answer to the cryopreservation headache. With a gel that's not just cool but doesn't need to be cold, they're setting cells, tissues, and viruses free from the icy grip of traditional storage and shipping methods. Welcome to the future of bioscience, where the storage is easy, and the cells are always fresh. Cell Storage, Cell Transport, Biomaterials, and Cellular Therapy

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Deliver on the promise of mRNA by providing a more flexible, cost-effective and sustainable manufacturing solution We are pioneering a revolutionary approach to enhance global healthcare access by simplifing and improving the production of mRNA vaccines and therapies.

66 similar entities Type: Startup Activities: healthtech deeptech Technologies: Decarbonization

A new generation of vaccines based on fusions of recombinant proteins A new generation of vaccines within animal health We develop vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile. Veterinary, Vaccines, Animal Health, Biotech, Recombinant Vaccines, Veterinary Products, Microbiology, Wholesale, and Research and Development

106 similar entities Type: Startup Activities: manufacturing healthtech deeptech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

114 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Dairy Done Differently Imagindairy, a Foodtech company, is addressing the industry bottleneck by integrating deep tech with system biology to develop a commercial and viable animal free protein-based dairy product

73 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines. …

64 similar entities Type: Startup Activities: biotech healthtech manufacturing Technologies: Synthetic Biology

Making it possible CLEAN BIOLOGICS is a CDMO for Viral vectors, Viral vaccines and oncolytic viruses and Biosafety testing for biological products. As well as a CMO for MCB & WCB production. GMP compliance

95 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

519 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Getting therapeutic proteins where they are needed most, in the CNS and beyond. Release Therapeutics is a preclinical-stage BioMedTech company developing the first cell macroencapsulation technology designed to deliver potent therapeutic proteins beyond the human blood-brain barrier.

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A sustainable delivery platform for oral biologics. Plantibodies is a biotech developing a sustainable platform to produce and deliver oral biologics with increased efficacy and less adverse side effects for the patients. Thanks to molecular farming and synthetic biology, our technology enables to produce humanized monoclonal antibodies within edible plant leaves instead of using animal cells, while drastically reducing carbon footprint, slashing production costs by over 90%, and offering medications with remarkable room temperature stability. By effortless storage and a potential worldwide distribution to treat diseases at home such as cancers, inflammations, metabolic diseases and infections, Plantibodies avoids burdensome intravenous …

61 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

565 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The network of bioproduction biotherapies integrators (RIBB) aims to coordinate, lead and assist the 8 integrators in the field of biotherapies and bioproduction, labeled as part of the “biotherapies and bioproduction of innovative therapies” (SABB) acceleration strategy so that they can respond to their technological platform missions on behalf of academic or industrial partners, and facilitate the industrialization of their technologies/products. Biotherapies, Bioproduction, Cell Therapy, Gene Therapy, and Extracellular Vesicles

209 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

113 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

The first registered vaccine against COVID-19 Sputnik V is the world’s first registered COVID-19 vaccine with proven 91.6% efficacy, based on a human adenoviral vector platform. Registered in over 70 countries.

76 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Smartox Biotechnology is specialized in peptide research and manufacturing Smartox Biotechnology is specialized in peptide research and engineering. Peptide synthesis, physiology, pharmacology, neuroscience, ion channel research, toxin, venomous animals, and screening library

297 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Revolutionising the delivery of fridge-free pharmaceuticals - StablevaXTM eliminates the need for the global cold chain Stablepharma Ltd is an innovative biopharmaceutical company developing a pipeline of fridge-free vaccine and pharmaceutical products. Stablepharma was founded with a simple purpose; to use its novel technology to dramatically improve health outcomes for those adults and children most at risk of death and disability caused by vaccine preventable diseases. StablevaX is an adaptable fridge-free technology which offers a greatly extended shelf-life, reduces vaccine wastage and CO2 emissions of the global cold-chain. The WHO estimate that approximately 50% of all vaccines manufactured are wasted …

59 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

120 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

140 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing what’s next in nutrition De Novo Foodlabs is a pioneering biotech start-up revolutionising the field of nutrition. Leveraging the power of microbial fermentation, the company creates innovative products that promote better health for both people and the planet. Food design, Product Development, Recombinant proteins, nutrition, health, and alternativeproteins

188 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Re-inventing immunotherapy for allergy Ukko is a biotechnology company dedicated to designing safe immunotherapies to rapidly treat allergies and other immune-mediated conditions. Our proprietary technology platform has the potential to reduce or eliminate potentially dangerous allergic reactions, while inducing a protective immune response. By rethinking how to prevent allergic reactions at the molecular level, we aim to develop a safer, more precise alternative to traditional allergy desensitization methods, starting with individuals at risk for life-threatening allergic reactions to peanut. Allergy, Peanut allergy, Immunotherapy, Immunology, and Biotechnology

59 similar entities Type: Startup Activities: foodtech Technologies: Synthetic Biology

Developing a new class of ADCs based on NMT inhibition to treat cancer We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

146 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Boosting the body's ability to defend against the damage of aging Five Alarm Bio is a drug discovery company based in Cambridge, UK focusing on novel approaches to anti-aging, with broad potential therapeutic application. We are researching therapeutics that boost the body's ability to defend against the damage of aging.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reversing Neurodegeneration - Restoring Life GeneCode is developing small-molecule drugs that bind and activate GDNF (Glial cell line-Derived Neurotrophic Factor) receptors for the treatment of Parkinson’s disease (PD) and other neurodegenerative conditions.

119 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Enabling Proteins for a Better Tomorrow Protevo Bio enables proteins for a better tomorrow. By solving the bottlenecks of conventional production processes, we make bioactive proteins available at large scales and low cost for cost-sensitive industrial applications.

74 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Enabling the next generation of medicines Lentivirus is challenging to manufacture. Unwanted transgene expression and viral genome instability are two common and critical issues. Lentitek can help you solve these challenges through a combination of expert design services and the incorporation of our unique manufacturing technology, which effectively eliminates unwanted transgene expression by stabilising the vector genome during the manufacturing process. Our approach enables you to optimise vector performance, enhance quality and safety, and minimise potentially hazardous off-target effects.

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Breaking Biology Free Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, including binders (nanobodies, bispecific antibodies), toxic proteins, and phage proteins.

165 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Nanovery - experts in nucleic acid quantification using nanorobots. We have created a proprietary Nucleic Acid Nanorobotics (NANs) platform that simplifies molecular testing and quantification for RNA therapeutics and biomarkers.

77 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Curileum is intervening early in serious gastrointestinal (GI) disease development with novel diagnostics & therapeutics Curileum is intervening early in serious GI disease development with novel therapeutics to detect and correct cell production in the gut mucosa Biotechnology

143 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We believe that everyone - irrespective of who they are or where they live - deserve medications that work We believe that everyone - irrespective of who they are or where they live - deserve medications that work

310 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the next generation of mRNA medicines. At Sensible, we are building the best-in-class mRNA design, optimisation and manufacturing platform to unlock the era of mRNA therapeutics and design-based biology.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Catalyzing Gene Therapy | Revolutionary Technology for Revolutionary Therapies At Fuse Vectors, our mission is to revolutionize AAV gene therapy development. Traditional cell-based technologies have hindered progress, posing challenges in safety, efficacy, development time, and cost. Our Cell-Free AAV technology surpasses these methods, producing safer, more effective, and cost-efficient AAV viral vectors in a fraction of the time.

68 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

514 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advancing the state-of-the-art in nature-based healthcare solutions Adamas Biotech exploits its core area of know-how, namely the anti-inflammatory, antioxidant and analgesic properties of green tea catechins to develop nutraceuticals and related products in the field of lower urinary tract symptoms and gastroenterology.

131 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Automation and standardization of cryopreservation processes for Cell Therapies Cellulis (formerly ZF Biotox) provides disruptive cryopreservation technologies in a broad range of biotechnology fields aiming to innovate CELL THERAPY solutions, to streamline BIOPROCESSING production, to enhance BIOBANKING and to improve High Throughput Screening (HTS) campaigns. Frozen Cells in Microplates Ready to Use., Final product formulation for cryopreserved cell therapy, and Cryopreservation of Cell Therapies

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Delivering longer, better quality lives for brain tumour patients QV Bioelectronics is a VC-backed medical device startup developing an implantable electric field therapy treatment for aggressive brain tumours.

114 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Protein Sciences (www.proteinsciences.com) is a biotechnology company that specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health by effectively responding to the changing world through the creation of innovative vaccines and biopharmaceuticals. See where Flublok® Influenza vaccine is available at www.flublok.com. We use our proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost. We have developed three main business lines that employ this technology: 1. Proprietary vaccines - we develop and produce the next generation of safer and more effective vaccines 2. GeneXpress® …

133 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Orchestrating gut health® EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

143 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Making Regenerative Medicine Accessible Roumai Medical is developing next-generation biotechnologies in regenerative medicine and human-machine interface to meet the unmet clinical needs of millions of patients worldwide.

207 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

535 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

a wholly owned subsidiary of Eli Lilly and Company LimmaTech Biologics AG, a wholly owned subsidiary of Eli Lilly and Company, is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. vaccines, research & development, biotechnology, and antimicrobial resistance

419 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We’re using ground-breaking cell technologies to revolutionise global food production - starting with pork Uncommon Bio began with cell-based meat and pioneered RNA delivery innovations, which evolved into their most recent spin out which is focusing on changing medicine through multi-targeting. Their polysaccharide-based delivery platform enables multi-pathway cell programming, offering a safe, efficient and scalable alternative to multi-target therapies. The company is initially targeting severe lung diseases like idiopathic pulmonary fibrosis and is backed by industry leaders from BioNTech and top investors, including Sam Altman, Balderton, Lowercarbon, and Redalpine. science+art, biotech, mRNA, IPF, Pulmonary fibrosis, and delivery

561 similar entities Type: Startup Activities: biotech deeptech foodtech Technologies: Synthetic Biology

Accelerating Global Health Through Bioscience Dalan's novel platform technology has introduced the world's first-ever honeybee vaccine, marking a pivotal milestone for the industry. Our mission is to safeguard the planet’s most underserved animal species, ensuring their continued well-being for global food security and the overall health of our planet.

82 similar entities Type: Startup Activities: pettech healthtech biotech Technologies: Synthetic Biology

Unlocking the next generation of biotech solutions (LON: BSFA). Unlocking the next generation of biotech solutions and financing the development of lab-grown meat, leather, human corneas, and skin substitutes (LON:BSFA). Owns 100% of 3D_BioTissues

59 similar entities Type: Startup Activities: deeptech

Multipathogen Vaccines To Protect Against Respiratory Viruses Vicebio is a clinical-stage biopharmaceutical company developing transformative multi-pathogen vaccines for respiratory viral infections. At the core of our work is Vicebio’s groundbreaking Molecular Clamp Technology, which locks viral proteins in their optimal conformation. This innovation enables our vaccines to deliver a unique combination of broad protection, ready-to-use administration, and convenient manufacturing. Our lead program is a best-in-class multivalent vaccine targeting five respiratory diseases, positioning Vicebio as a leader in multipathogen respiratory vaccines. Vaccines, Structural vaccinology, respiratory viruses, RSV, Influenza, SARS-Cov-2, Metapneumovirus, and Parainfluenza

65 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Exploiting a new class of tumour specific antigens for cancer therapy A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen. TCR-T cells, Immuno-oncology, Vaccines, Bi-specifics, Splicing, Epigenetics, Oncology, T cell biology, and Antigen presentation

178 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Creating biologicals without refrigeration. Our patented novel Ensilication technology uses silica to create an individually tailored protective nanoshell around vaccines, antibodies and enzymes to prevent degradation, which can lead to spoilage. Once applied, the material can be stored and transported without the need for cold chain infrastructure, improving global access to medicines and reducing wastage and emissions across the pharmaceutical supply chain. Ensilication preserves the integrity of a wide variety of biomolecules and proteins, not only protecting against environmental degradation, but also making possible the development of more convenient administration such as subcutaneous and oral delivery for both humans and …

93 similar entities Type: Startup Activities: deeptech transporttech Technologies: Synthetic Biology

Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients Delivering local-acting immunotherapies to patients ATMP, Gene Therapy, Drug development, Clinical trials, GMP, IBD, Wound treatment, Scar, Topical, Oral, Research, Science, Immunology, Immunophysiology, microbiology, Applied microbiology, Regulatory excellence, Skin, Diabetes, IBD, Cysticfibrosis, SAVI, colitis, Cystic fibrosis, and Inhalation

646 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sustainable circular-derived protein | Clean-label ingredients for alt-protein & cultivated meat | High Quality Cells An ingredients company providing sustainable, scalable and delicious solutions for alternative protein and cultured meat.

70 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

132 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advancing iPSC-derived cell therapies to transform care in autoimmune disease and cancer​ Century Therapeutics is an innovative biotechnology company that is building an industry-leading, allogeneic, iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.​ Please note: Century Therapeutics does not solicit prospective Colleagues directly via Telegram (or other social media sites) or require potential candidates to make purchases of goods or services.​

65 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Better Access. Better Lives. Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars. Biopharmaceuticals, Research and Development, Biosimilars, Biotechnology, Pharmaceutical, Biogenerics, Health, Cell Line Development, Business Development, and Regulatory

418 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Uniqueness of Individualized Neoantigen Cancer Vaccine to Reshape the Future of Early-Stage Cancer Treatment Cancer immunotherapy Transgene (Euronext: TNG) is a clinical-stage biotechnology company focused on individualized therapeutic vaccines

166 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering Antibody Innovations to Defeat Cancer At VERAXA Biotech (NASDAQ:VRXA), we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including antibody-drug conjugates (ADCs), bispecific T cell engagers (BiTAC TCEs), and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA Biotech was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technologies. Cancer Research, Drug Development, …

192 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Oak Hill Bio's mission is to develop life-changing medicines for patients suffering from rare diseases Oak Hill Bio is a clinical-stage biotech company committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ovagen is a biotechnology company that has developed a proprietary process of producing Germ Free chicken eggs and Germ Free birds in commercial quantities for use primarily in the vaccine and pharmaceutical industry.

70 similar entities Type: SMB Activities: pettech healthtech Technologies: Synthetic Biology

Research company, GMP manufacturer & global supplier of live vaccines to the intensively farmed food animal industry. Bioproperties Pty Ltd is a leading Australian novel vaccine research company (Melbourne), GMP manufacturer (Sydney) and global supplier of live vaccines to the intensively farmed food animal industry.

58 similar entities Type: SMB Activities: foodtech deeptech Technologies: Synthetic Biology

Autogenous Vaccines Specialists Ridgeway Biologicals are licensed by the VMD (Veterinary Medicines Directorate) to manufacture autogenous vaccine which are veterinary prescription only medicines. Autogenous vaccines are prepared from a pathogen extracted from a host animal or group which is then used to inoculate the rest of the group. We are able to manufacture autogenous vaccine for many farm animals and fish. For more information on autogenous vaccines please contact your veterinary surgeon. autogenous veterinary vaccines

58 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Helping people live longer, healthier lives. Centenara Labs is a clinical-stage biotechnology company creating therapies to improve healthy aging. Its experienced drug discovery and development team applies a deep understanding of the biology of aging, alongside technological advances in biopharmaceutical R&D, to progress a new generation of medicines that will help people to age better and live longer.

66 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Developing next-generation lipid nanoparticle delivery systems to unlock the potential of RNA therapeutics Axelyf was founded in Iceland in 2022 with the goal of harnessing health benefits of natural molecules through chemistry and delivery engineering.

169 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology